Is A Body Shape Index (ABSI) associated with incident cancer? – Findings from the UK Biobank prospective cohort study
Session type: E-poster/poster
Body mass index (BMI) has been the most commonly used marker of adiposity investigated for cancer risk. There is limited evidence on associations with emerging adiposity markers, such as A Body Shape Index (ABSI). ABSI is a measure of body shape that is independent of BMI. This study investigated associations of ABSI with incidence of 24 cancers
442 614 participants (53.7% women; mean age 56.3 years) from the UK Biobank prospective cohort study were included in this study. ABSI was sex-standardised and used as exposure. Cox proportional hazard models were used to explore associations between ABSI and incidence of cancers at 24 sites and overall cancer risk.
The median follow-up period was 8.8 years (interquartile range 7.9 to 9.6). 36 961 individuals developed cancer over the follow-up period. ABSI was slightly correlated with BMI (r=0.12, p=<0.001). Participants in the highest tertile of ABSI had higher risk of liver (HR: 1.38 [95% CI: 1.26; 1.52]), lung (HR: 1.41 [95% CI: 1.16; 1.73]), colorectal (HR: 1.18 [95% CI: 1.09; 1.27]) and overall (HR: 1.09 [95% CI: 1.06; 1.12) cancer compared with the lowest tertile, after adjustment for BMI. When ABSI was combined with BMI, participants in the highest ABSI who also had a BMI≥25kg/m2 were at greater risk of uterus (HR: 2.30 [1.89; 2.80]), oesophagus (1.68 [1.31; 2.15]), liver (HR: 1.46 [1.11; 1.91]), stomach (HR: 1.58 [1.20; 2.06]), kidney (HR: 1.59 [1.30; 1.96]), colorectal (HR: 1.29 [1.17; 1.42]) and breast cancers (HR: 1.22 [1.14; 1.31])) and overall cancer (HR: 1.13 [1.10; 1.17]) compared with those in the lowest ABSI tertile with a normal BMI.
After adjustment for BMI, ABSI, was associated with increased risk for three cancer sites. However, the combination with BMI had an association with seven cancer sites
Having a higher ABSI and excess body weight (defined as BMI ≥25) was associated with greater risk of cancer at seven sites, including uterus, oesophagus, liver, stomach, kidney, colorectal and breast.